K Andersson

Summary

Affiliation: University of Turku
Country: Finland

Publications

  1. ncbi Plasma tacrine concentrations are significantly increased by concomitant hormone replacement therapy
    K Laine
    Department of Pharmacology and Clinical Pharmacology, University of Turku, Finland
    Clin Pharmacol Ther 66:602-8. 1999
  2. ncbi Severe adverse effects in a newborn with two defective CYP2D6 alleles after exposure to paroxetine during late pregnancy
    Kari Laine
    Department of Pharmacology and Clinical Pharmacology, University of Turku, Turku, Finland
    Ther Drug Monit 26:685-7. 2004
  3. ncbi Effect of the novel anxiolytic drug deramciclane on cytochrome P(450) 2D6 activity as measured by desipramine pharmacokinetics
    Kari Laine
    Department of Pharmacology and Clinical Pharmacology, University of Turku, It Pitkäkatu 4B, 20520 Turku, Finland
    Eur J Clin Pharmacol 59:893-8. 2004
  4. ncbi Effect of the novel anxiolytic drug deramciclane on the pharmacokinetics and pharmacodynamics of the CYP3A4 probe drug buspirone
    Kari Laine
    Department of Pharmacology and Clinical Pharmacology, University of Turku, It Pitkäkatu 4B, FIN 20520, Turku, Finland
    Eur J Clin Pharmacol 59:761-6. 2003
  5. ncbi A screening study on the liability of eight different female sex steroids to inhibit CYP2C9, 2C19 and 3A4 activities in human liver microsomes
    Kari Laine
    Department of Medical Laboratory Sciences and Technology, Division of Clinical Pharmacology, Karolinska Institutet, Huddinge University Hospital, Stockholm, Sweden
    Pharmacol Toxicol 93:77-81. 2003
  6. ncbi Effects of exposure to selective serotonin reuptake inhibitors during pregnancy on serotonergic symptoms in newborns and cord blood monoamine and prolactin concentrations
    Kari Laine
    Department of Pharmacology and Clinical Pharmacology, University of Turku and Turku University Central Hospital, Turku, Finland
    Arch Gen Psychiatry 60:720-6. 2003
  7. ncbi Inhibition of cytochrome P4502D6 activity with paroxetine normalizes the ultrarapid metabolizer phenotype as measured by nortriptyline pharmacokinetics and the debrisoquin test
    K Laine
    Department of Medical Laboratory Sciences and Technology, Division of Clinical Pharmacology, Karolinska Institutet, Huddinge University Hospital, Huddinge, Sweden
    Clin Pharmacol Ther 70:327-35. 2001
  8. ncbi CYP2C19 polymorphism is not important for the in vivo metabolism of selegiline
    K Laine
    Department of Pharmacology and Clinical Pharmacology, University of Turku, Kiinamyllynkatu 10, 20520 Turku, Finland
    Eur J Clin Pharmacol 57:137-42. 2001
  9. ncbi No sex-related differences but significant inhibition by oral contraceptives of CYP2C19 activity as measured by the probe drugs mephenytoin and omeprazole in healthy Swedish white subjects
    K Laine
    Department of Medical Laboratory Sciences and Technology, Karolinska Institutet, Huddinge University Hospital, Sweden
    Clin Pharmacol Ther 68:151-9. 2000
  10. ncbi [Genetic mutation as a risk factor for a patient treated with warfarin]
    Kari Laine
    Turun yliopiisto ja TYKS, kliininen farmakologia, PharmaCity, Turku
    Duodecim 121:177-80. 2005

Detail Information

Publications10

  1. ncbi Plasma tacrine concentrations are significantly increased by concomitant hormone replacement therapy
    K Laine
    Department of Pharmacology and Clinical Pharmacology, University of Turku, Finland
    Clin Pharmacol Ther 66:602-8. 1999
    ..Moreover, HRT has been reported to enhance response to tacrine in postmenopausal patients with Alzheimer's disease, but the mechanism of this interaction remains unclear...
  2. ncbi Severe adverse effects in a newborn with two defective CYP2D6 alleles after exposure to paroxetine during late pregnancy
    Kari Laine
    Department of Pharmacology and Clinical Pharmacology, University of Turku, Turku, Finland
    Ther Drug Monit 26:685-7. 2004
    ....
  3. ncbi Effect of the novel anxiolytic drug deramciclane on cytochrome P(450) 2D6 activity as measured by desipramine pharmacokinetics
    Kari Laine
    Department of Pharmacology and Clinical Pharmacology, University of Turku, It Pitkäkatu 4B, 20520 Turku, Finland
    Eur J Clin Pharmacol 59:893-8. 2004
    ....
  4. ncbi Effect of the novel anxiolytic drug deramciclane on the pharmacokinetics and pharmacodynamics of the CYP3A4 probe drug buspirone
    Kari Laine
    Department of Pharmacology and Clinical Pharmacology, University of Turku, It Pitkäkatu 4B, FIN 20520, Turku, Finland
    Eur J Clin Pharmacol 59:761-6. 2003
    ..Moreover, its co-administration with buspirone, another anxiolytic drug, is likely in clinical practice...
  5. ncbi A screening study on the liability of eight different female sex steroids to inhibit CYP2C9, 2C19 and 3A4 activities in human liver microsomes
    Kari Laine
    Department of Medical Laboratory Sciences and Technology, Division of Clinical Pharmacology, Karolinska Institutet, Huddinge University Hospital, Stockholm, Sweden
    Pharmacol Toxicol 93:77-81. 2003
    ....
  6. ncbi Effects of exposure to selective serotonin reuptake inhibitors during pregnancy on serotonergic symptoms in newborns and cord blood monoamine and prolactin concentrations
    Kari Laine
    Department of Pharmacology and Clinical Pharmacology, University of Turku and Turku University Central Hospital, Turku, Finland
    Arch Gen Psychiatry 60:720-6. 2003
    ..We aimed to investigate the perinatal sequelae of infants exposed to SSRIs during their fetal life and the relationship of these symptoms to the cord blood monoamine and prolactin concentrations...
  7. ncbi Inhibition of cytochrome P4502D6 activity with paroxetine normalizes the ultrarapid metabolizer phenotype as measured by nortriptyline pharmacokinetics and the debrisoquin test
    K Laine
    Department of Medical Laboratory Sciences and Technology, Division of Clinical Pharmacology, Karolinska Institutet, Huddinge University Hospital, Huddinge, Sweden
    Clin Pharmacol Ther 70:327-35. 2001
    ..Normalization of the metabolic status of ultrarapid metabolizers by inhibition of CYP2D6 activity could offer a clinically acceptable method to successfully treat such patients with antidepressants...
  8. ncbi CYP2C19 polymorphism is not important for the in vivo metabolism of selegiline
    K Laine
    Department of Pharmacology and Clinical Pharmacology, University of Turku, Kiinamyllynkatu 10, 20520 Turku, Finland
    Eur J Clin Pharmacol 57:137-42. 2001
    ..To address the relevance of cytochrome P-450 (CYP) 2C19 polymorphism for the pharmacokinetics and dynamics of selegiline and its two known primary metabolites, desmethylselegiline and l-methamphetamine...
  9. ncbi No sex-related differences but significant inhibition by oral contraceptives of CYP2C19 activity as measured by the probe drugs mephenytoin and omeprazole in healthy Swedish white subjects
    K Laine
    Department of Medical Laboratory Sciences and Technology, Karolinska Institutet, Huddinge University Hospital, Sweden
    Clin Pharmacol Ther 68:151-9. 2000
    ..Moreover, earlier reports suggest that there may be differences in CYP2C19 activity between men and women...
  10. ncbi [Genetic mutation as a risk factor for a patient treated with warfarin]
    Kari Laine
    Turun yliopiisto ja TYKS, kliininen farmakologia, PharmaCity, Turku
    Duodecim 121:177-80. 2005